Genocea Biosciences, Inc. (NASDAQ:GNCA – Get Free Report) crossed above its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of $0.00 and traded as high as $0.0001. Genocea Biosciences shares last traded at $0.00, with a volume of 0 shares trading hands.
Genocea Biosciences Stock Down 100.0%
The company has a debt-to-equity ratio of 0.24, a current ratio of 1.35 and a quick ratio of 1.35. The firm has a market cap of $6,000.00, a PE ratio of 0.00 and a beta of 1.61.
Genocea Biosciences Company Profile
Genocea Biosciences, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel T cell-directed therapies and vaccines for oncology and infectious diseases. Headquartered in Cambridge, Massachusetts, Genocea aims to leverage the body’s natural immune response by identifying the precise antigens that drive protective T cell activity.
The company’s proprietary ATLAS platform enables comprehensive mapping of antigen-specific CD4+ and CD8+ T cell responses.
See Also
- Five stocks we like better than Genocea Biosciences
- Abercrombie Rallies as Strong Q1 Earnings Extend Winning Streak
- TeraWulf Bets on Power Infrastructure to Lead AI Build-Out
- Amazon’s Alexa for Shopping Strengthens an Already Strong Bull Case
- Keysight: The AI and Defense Stock Seeing Big Price Target Boosts
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
